» Articles » PMID: 37751487

The Value of Folate Receptor-positive Circulating Tumour Cells As a Diagnostic Biomarker for Lung Cancer: a Systematic Review and Meta-analysis

Overview
Journal J Int Med Res
Publisher Sage Publications
Specialty General Medicine
Date 2023 Sep 26
PMID 37751487
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To conduct a systematic review and meta-analysis evaluating the diagnostic value of folate receptor-positive (FR+) circulating tumour cells (CTCs) as a potential tumour marker for lung cancer diagnosis.

Methods: The PubMed, Embase, and Web of Science databases were searched for relevant articles published between database inception and November 2022. Eligible studies were selected based on inclusion and exclusion criteria. Sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio, and area under the curve (AUC) were pooled with 95% confidence intervals (CI), using RevMan 5.4 and STATA 17.0 software to assess the diagnostic value of FR+CTC for lung cancer.

Results: After screening, 11 studies involving 3469 subjects were eligible for inclusion. The pooled sensitivity and specificity were 0.79 (95% CI 0.76, 0.82) and 0.84 (95% CI 0.81, 0.96), respectively, and the pooled positive and negative likelihood ratios were 4.90 (95% CI 4.25, 5.65) and 0.25 (95% CI 0.22, 0.29), respectively. The pooled diagnostic odds ratio was 19.70 (95% CI 16.06, 24.16). The AUC of the pooled summary receiver operating characteristic curve was 0.89 (95% CI 0.85, 0.91). Sensitivity analysis showed that this result was stable after one-by-one study elimination.

Conclusion: Folate receptor-positive CTCs may have good diagnostic value in lung cancer.

Citing Articles

The latest advances in liquid biopsy for lung cancer-a narrative review.

She W, Garitaonaindia Y, Lin Y Transl Lung Cancer Res. 2024; 13(11):3241-3251.

PMID: 39669995 PMC: 11632431. DOI: 10.21037/tlcr-24-828.


Folate Receptor Alpha-A Novel Approach to Cancer Therapy.

Gonzalez T, Muminovic M, Nano O, Vulfovich M Int J Mol Sci. 2024; 25(2).

PMID: 38256120 PMC: 11154542. DOI: 10.3390/ijms25021046.

References
1.
Li N, Zhong D, Chen H, Huang T, Hou P, Zhang Y . The utility of folate receptor-positive circulating tumor cell in cancer diagnosis in the elderly population. Cancer Manag Res. 2019; 11:4097-4107. PMC: 6511626. DOI: 10.2147/CMAR.S184532. View

2.
Xue Y, Cong W, Xie S, Shu J, Feng G, Gao H . Folate-receptor-positive circulating tumor cells as an efficacious biomarker for the diagnosis of small pulmonary nodules. J Cancer Res Ther. 2018; 14(7):1620-1626. DOI: 10.4103/jcrt.JCRT_905_17. View

3.
Li H, Li B, Pan Y, Zhang Y, Xiang J, Zhang Y . Preoperative Folate Receptor-Positive Circulating Tumor Cell Level Is a Prognostic Factor of Long Term Outcome in Non-Small Cell Lung Cancer Patients. Front Oncol. 2021; 10:621435. PMC: 7876466. DOI: 10.3389/fonc.2020.621435. View

4.
Zhou Q, Geng Q, Wang L, Huang J, Liao M, Li Y . Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness. EBioMedicine. 2019; 41:236-243. PMC: 6442989. DOI: 10.1016/j.ebiom.2019.02.028. View

5.
Lyu M, Zhou J, Ning K, Ying B . The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer. Onco Targets Ther. 2019; 12:2539-2552. PMC: 6454989. DOI: 10.2147/OTT.S195342. View